

# Daniel J Rader

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6819682/publications.pdf>

Version: 2024-02-01

445  
papers

72,381  
citations

668

122  
h-index

677

254  
g-index

470  
all docs

470  
docs citations

470  
times ranked

54456  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Genome-First Approach to Rare Variants in Dominant Postlingual Hearing Loss Genes in a Large Adult Population. <i>Otolaryngology - Head and Neck Surgery</i> , 2022, 166, 746-752.	1.9	3
2	Associations of Endogenous Hormones With HDL Novel Metrics Across the Menopause Transition: The SWAN HDL Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e303-e314.	3.6	5
3	LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e57-e70.	3.6	29
4	A genome-first approach to rare variants in hypertrophic cardiomyopathy genes <i>MYBPC3</i> and <i>MYH7</i> in a medical biobank. <i>Human Molecular Genetics</i> , 2022, 31, 827-837.	2.9	4
5	Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. <i>European Urology</i> , 2022, 81, 559-567.	1.9	17
6	Cytomegalovirus Latent Infection is Associated with an Increased Risk of COVID-19-Related Hospitalization. <i>Journal of Infectious Diseases</i> , 2022, 226, 463-473.	4.0	39
7	Rare coding variants in 35 genes associate with circulating lipid levels—A multi-ancestry analysis of 170,000 exomes. <i>American Journal of Human Genetics</i> , 2022, 109, 81-96.	6.2	24
8	Web of Science™s Citation Median Metrics Overcome the Major Constraints of the Journal Impact Factor. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 367-371.	2.4	2
9	Coronary Artery Disease Risk of Familial Hypercholesterolemia Genetic Variants Independent of Clinically Observed Longitudinal Cholesterol Exposure. <i>Circulation Genomic and Precision Medicine</i> , 2022, 15, CIRCGEN121003501.	3.6	6
10	Sortilin restricts secretion of apolipoprotein B-100 by hepatocytes under stressed but not basal conditions. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	11
11	Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease. <i>Nature Genetics</i> , 2022, 54, 382-392.	21.4	97
12	Associations of Abdominal and Cardiovascular Adipose Tissue Depots With HDL Metrics in Midlife Women: the SWAN Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2245-e2257.	3.6	2
13	Whole-genome sequencing reveals host factors underlying critical COVID-19. <i>Nature</i> , 2022, 607, 97-103.	27.8	174
14	The Relationship Between Lipoproteins and Insulin Sensitivity in Youth With Obesity and Abnormal Glucose Tolerance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1541-1551.	3.6	9
15	Endothelial plasticity drives aberrant vascularization and impedes cardiac repair after myocardial infarction. , 2022, 1, 372-388.		9
16	Impact of natural selection on global patterns of genetic variation and association with clinical phenotypes at genes involved in SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2123000119.	7.1	7
17	High heritability of ascending aortic diameter and trans-ancestry prediction of thoracic aortic disease. <i>Nature Genetics</i> , 2022, 54, 772-782.	21.4	29
18	A multi-ancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. <i>Nature Genetics</i> , 2022, 54, 761-771.	21.4	68

#	ARTICLE	IF	CITATIONS
19	Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries. <i>Nature Genetics</i> , 2022, 54, 1103-1116.	21.4	54
20	Genetics of Postlingual Sensorineural Hearing Loss. <i>Laryngoscope</i> , 2021, 131, 401-409.	2.0	17
21	Polygenic Risk of Psychiatric Disorders Exhibits Cross-trait Associations in Electronic Health Record Data From European Ancestry Individuals. <i>Biological Psychiatry</i> , 2021, 89, 236-245.	1.3	26
22	HDL (High-Density Lipoprotein) Subclasses, Lipid Content, and Function Trajectories Across the Menopause Transition. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 951-961.	2.4	29
23	Rates of COVID-19-Related Outcomes in Cancer Compared With Noncancer Patients. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa120.	2.9	26
24	Exome-wide evaluation of rare coding variants using electronic health records identifies new gene-phenotype associations. <i>Nature Medicine</i> , 2021, 27, 66-72.	30.7	44
25	Quantification of abdominal fat from computed tomography using deep learning and its association with electronic health records in an academic biobank. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 1178-1187.	4.4	14
26	Disrupting upstream translation in mRNAs is associated with human disease. <i>Nature Communications</i> , 2021, 12, 1515.	12.8	37
27	Genome-first approach to rare EYA4 variants and cardio-auditory phenotypes in adults. <i>Human Genetics</i> , 2021, 140, 957-967.	3.8	7
28	A Mendelian randomization study of the role of lipoprotein subfractions in coronary artery disease. <i>ELife</i> , 2021, 10, .	6.0	25
29	Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. <i>Cell</i> , 2021, 184, 1858-1864.e10.	28.9	332
30	Nuclear receptors FXR and SHP regulate protein N-glycan modifications in the liver. <i>Science Advances</i> , 2021, 7, .	10.3	6
31	ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1753-1759.	2.4	60
32	A randomized controlled trial of genetic testing and cascade screening in familial hypercholesterolemia. <i>Genetics in Medicine</i> , 2021, 23, 1697-1704.	2.4	11
33	SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. <i>JCO Oncology Practice</i> , 2021, 17, e1879-e1886.	2.9	2
34	Unbiased Analysis of Temporal Changes in Immune Serum Markers in Acute COVID-19 Infection With Emphasis on Organ Failure, Anti-Viral Treatment, and Demographic Characteristics. <i>Frontiers in Immunology</i> , 2021, 12, 650465.	4.8	19
35	Association Between Genetic Variation in Blood Pressure and Increased Lifetime Risk of Peripheral Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2027-2034.	2.4	24
36	Lipid droplet screen in human hepatocytes identifies TRRAP as a regulator of cellular triglyceride metabolism. <i>Clinical and Translational Science</i> , 2021, 14, 1369-1379.	3.1	4

#	ARTICLE	IF	CITATIONS
37	Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals. <i>American Journal of Human Genetics</i> , 2021, 108, 1350-1355.	6.2	72
38	Sequencing of 640,000 exomes identifies <i>GPR75</i> variants associated with protection from obesity. <i>Science</i> , 2021, 373, .	12.6	130
39	Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration. <i>JCI Insight</i> , 2021, 6, .	5.0	22
40	Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease. <i>Circulation</i> , 2021, 144, 353-364.	1.6	47
41	Hepatic Manifestations of Mendelian Disorders of Cholesterol Biosynthesis and Cellular Metabolism. <i>Clinical Liver Disease</i> , 2021, 18, 266-273.	2.1	0
42	Individual-specific functional epigenomics reveals genetic determinants of adverse metabolic effects of glucocorticoids. <i>Cell Metabolism</i> , 2021, 33, 1592-1609.e7.	16.2	15
43	Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	51
44	Endothelial lipase mediates efficient lipolysis of triglyceride-rich lipoproteins. <i>PLoS Genetics</i> , 2021, 17, e1009802.	3.5	18
45	Rare, Damaging DNA Variants in <i>CORIN</i> and Risk of Coronary Artery Disease: Insights From Functional Genomics and Large-Scale Sequencing Analyses. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003399.	3.6	10
46	Genetics of Smoking and Risk of Atherosclerotic Cardiovascular Diseases. <i>JAMA Network Open</i> , 2021, 4, e2034461.	5.9	42
47	Assessing HDL Metabolism in Subjects with Elevated Levels of HDL Cholesterol and Coronary Artery Disease. <i>Molecules</i> , 2021, 26, 6862.	3.8	3
48	MitoScape: A big-data, machine-learning platform for obtaining mitochondrial DNA from next-generation sequencing data. <i>PLoS Computational Biology</i> , 2021, 17, e1009594.	3.2	11
49	TRIB1 regulates LDL metabolism through CEBP $\mu$ -mediated effects on the LDL receptor in hepatocytes. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	9
50	Multi-Trait Genome-Wide Association Study of Atherosclerosis Detects Novel Pleiotropic Loci. <i>Frontiers in Genetics</i> , 2021, 12, 787545.	2.3	3
51	Implementation of a Machine-Learning Algorithm in the Electronic Health Record for Targeted Screening for Familial Hypercholesterolemia: A Quality Improvement Study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007641.	2.2	7
52	A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes. <i>Genetics in Medicine</i> , 2020, 22, 102-111.	2.4	42
53	Genomic profiling of human vascular cells identifies TWIST1 as a causal gene for common vascular diseases. <i>PLoS Genetics</i> , 2020, 16, e1008538.	3.5	40
54	Annual Report on Sex in Preclinical Studies. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, e1-e9.	2.4	8

#	ARTICLE	IF	CITATIONS
55	Genetic Architecture of Abdominal Aortic Aneurysm in the Million Veteran Program. <i>Circulation</i> , 2020, 142, 1633-1646.	1.6	78
56	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. <i>PLoS Medicine</i> , 2020, 17, e1003288.	8.4	51
57	Lack of pathogenic germline DICER1 variants in males with testicular germ-cell tumors. <i>Cancer Genetics</i> , 2020, 248-249, 49-56.	0.4	0
58	Teaching Old Drugs New Tricks: Statins for COVID-19?. <i>Cell Metabolism</i> , 2020, 32, 145-147.	16.2	29
59	SARS-CoV-2 seroprevalence among parturient women in Philadelphia. <i>Science Immunology</i> , 2020, 5, .	11.9	121
60	Heterozygous <i>ABCG5</i> Gene Deficiency and Risk of Coronary Artery Disease. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, 417-423.	3.6	45
61	Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program. <i>PLoS ONE</i> , 2020, 15, e0237430.	2.5	15
62	Mendelian Randomization Analysis of Hemostatic Factors and Their Contribution to Peripheral Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 41, 380-386.	2.4	14
63	Self-Organizing Human Induced Pluripotent Stem Cell Hepatocyte 3D Organoids Inform the Biology of the Pleiotropic <i>TRIB1</i> Gene. <i>Hepatology Communications</i> , 2020, 4, 1316-1331.	4.3	6
64	<i>ILRUN</i> , a Human Plasma Lipid GWAS Locus, Regulates Lipoprotein Metabolism in Mice. <i>Circulation Research</i> , 2020, 127, 1347-1361.	4.5	11
65	Anti-inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e016507.	3.7	21
66	LDL-Cholesterol Reduction by <i>ANGPTL3</i> Inhibition in Mice Is Dependent on Endothelial Lipase. <i>Circulation Research</i> , 2020, 127, 1112-1114.	4.5	46
67	4365 Family-Based Study of Sleep in Autism Spectrum Disorder without Intellectual Disability. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 72-72.	0.6	0
68	<i>EDEM3</i> Modulates Plasma Triglyceride Level through Its Regulation of <i>LRP1</i> Expression. <i>IScience</i> , 2020, 23, 100973.	4.1	8
69	Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. <i>Nature Genetics</i> , 2020, 52, 680-691.	21.4	445
70	Systematically Sifting Big Data to Identify Novel Causal Genes for Human Traits. <i>Cell Metabolism</i> , 2020, 31, 658-659.	16.2	0
71	Antisense oligonucleotides for atherosclerotic disease. <i>Nature Medicine</i> , 2020, 26, 471-472.	30.7	3
72	Novel congenital disorder of <i>O</i> -linked glycosylation caused by <i>GALNT2</i> loss of function. <i>Brain</i> , 2020, 143, 1114-1126.	7.6	46

#	ARTICLE	IF	CITATIONS
73	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. , 2020, 17, e1003288.		0
74	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. , 2020, 17, e1003288.		0
75	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. , 2020, 17, e1003288.		0
76	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. , 2020, 17, e1003288.		0
77	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. , 2020, 17, e1003288.		0
78	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>Cardiovascular Research</i> , 2019, 115, 204-212.	3.8	34
79	Association of <i>APOL1</i> Risk Alleles With Cardiovascular Disease in Blacks in the Million Veteran Program. <i>Circulation</i> , 2019, 140, 1031-1040.	1.6	31
80	Genome-wide association study of peripheral artery disease in the Million Veteran Program. <i>Nature Medicine</i> , 2019, 25, 1274-1279.	30.7	177
81	Myeloid Tribbles 1 induces early atherosclerosis via enhanced foam cell expansion. <i>Science Advances</i> , 2019, 5, eaax9183.	10.3	50
82	Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. <i>Nature Genetics</i> , 2019, 51, 1574-1579.	21.4	152
83	Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data. <i>The Lancet Digital Health</i> , 2019, 1, e393-e402.	12.3	49
84	Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 ( <i>CHEK2</i> ) With Susceptibility to Testicular Germ Cell Tumors. <i>JAMA Oncology</i> , 2019, 5, 514.	7.1	43
85	Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD. <i>American Journal of Kidney Diseases</i> , 2019, 73, 827-836.	1.9	43
86	N-Glycosylation Defects in Humans Lower Low-Density Lipoprotein Cholesterol Through Increased Low-Density Lipoprotein Receptor Expression. <i>Circulation</i> , 2019, 140, 280-292.	1.6	26
87	Genetic and Epigenetic Fine Mapping of Complex Trait Associated Loci in the Human Liver. <i>American Journal of Human Genetics</i> , 2019, 105, 89-107.	6.2	35
88	Genomics-First Evaluation of Heart Disease Associated With Titin-Truncating Variants. <i>Circulation</i> , 2019, 140, 42-54.	1.6	97
89	Soluble FMS-Like Tyrosine Kinase-1 Is a Circulating Biomarker Associated With Calcific Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1364-1365.	2.8	2
90	Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. <i>Nature Communications</i> , 2019, 10, 1499.	12.8	346

#	ARTICLE	IF	CITATIONS
91	Manganese homeostasis: from rare single-gene disorders to complex phenotypes and diseases. <i>Journal of Clinical Investigation</i> , 2019, 129, 5082-5085.	8.2	16
92	A Targeted, Differential Top-Down Proteomic Methodology for Comparison of ApoA-I Proteoforms in Individuals with High and Low HDL Efflux Capacity. <i>Journal of Proteome Research</i> , 2018, 17, 2156-2164.	3.7	30
93	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 177-192.	2.8	337
94	Autophagy Is Required for Sortilin-Mediated Degradation of Apolipoprotein B100. <i>Circulation Research</i> , 2018, 122, 568-582.	4.5	35
95	A Protein-Truncating <i>HSD17B13</i> Variant and Protection from Chronic Liver Disease. <i>New England Journal of Medicine</i> , 2018, 378, 1096-1106.	27.0	556
96	Lipoprotein Disorders. , 2018, , 27-46.		1
97	Mining the Stiffness-Sensitive Transcriptome in Human Vascular Smooth Muscle Cells Identifies Long Noncoding RNA Stiffness Regulators. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 164-173.	2.4	43
98	Trials and Tribulations of CETP Inhibitors. <i>Circulation Research</i> , 2018, 122, 106-112.	4.5	210
99	Role of angiotensin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. <i>Atherosclerosis</i> , 2018, 268, 196-206.	0.8	81
100	Interrogation of the Atherosclerosis-Associated <i>SORT1</i> (Sortilin 1) Locus With Primary Human Hepatocytes, Induced Pluripotent Stem Cell-Hepatocytes, and Locus-Humanized Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 76-82.	2.4	28
101	2003 Mixed meal effects of neprilysin inhibition. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 44-44.	0.6	0
102	Genomic Risk Stratification Predicts All-Cause Mortality After Cardiac Catheterization. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002352.	3.6	16
103	Genetic Variants Associated With Plasma Lipids Are Associated With the Lipid Response to Niacin. <i>Journal of the American Heart Association</i> , 2018, 7, e03488.	3.7	8
104	FP526VASCULAR CXCR4 LIMITS ATHEROSCLEROSIS BY MAINTAINING ARTERIAL INTEGRITY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i216-i216.	0.7	1
105	Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. <i>Nature Genetics</i> , 2018, 50, 1514-1523.	21.4	497
106	Multiplexed Targeted Resequencing Identifies Coding and Regulatory Variation Underlying Phenotypic Extremes of High-Density Lipoprotein Cholesterol in Humans. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002070.	3.6	5
107	Clinical Genetic Testing for Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2018, 72, 662-680.	2.8	387
108	Apolipoprotein A-I Infusion Therapies for Coronary Disease. <i>JAMA Cardiology</i> , 2018, 3, 799.	6.1	26

#	ARTICLE	IF	CITATIONS
109	Directional ABCA1-mediated cholesterol efflux and apoB-lipoprotein secretion in the retinal pigment epithelium. <i>Journal of Lipid Research</i> , 2018, 59, 1927-1939.	4.2	21
110	Multi-ethnic genome-wide association study for atrial fibrillation. <i>Nature Genetics</i> , 2018, 50, 1225-1233.	21.4	552
111	Zinc transporter Slc39a8 is essential for cardiac ventricular compaction. <i>Journal of Clinical Investigation</i> , 2018, 128, 826-833.	8.2	39
112	Biomarkers of Calcific Aortic Valve Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 623-632.	2.4	63
113	A novel approach to measuring macrophage-specific reverse cholesterol transport in vivo in humans. <i>Journal of Lipid Research</i> , 2017, 58, 752-762.	4.2	22
114	Overexpression and deletion of phospholipid transfer protein reduce HDL mass and cholesterol efflux capacity but not macrophage reverse cholesterol transport. <i>Journal of Lipid Research</i> , 2017, 58, 731-741.	4.2	13
115	Intracoronary Imaging, Reverse Cholesterol Transport, and Transcriptomics. <i>Journal of the American College of Cardiology</i> , 2017, 69, 641-643.	2.8	2
116	Mediterranean Approach to Improving High-Density Lipoprotein Function. <i>Circulation</i> , 2017, 135, 644-647.	1.6	5
117	Deep Apolipoprotein Proteomics to Uncover Mechanisms of Coronary Disease Risk. <i>Journal of the American College of Cardiology</i> , 2017, 69, 801-804.	2.8	4
118	Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 823-836.	2.8	214
119	Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. <i>Nature</i> , 2017, 544, 235-239.	27.8	292
120	Hepatic protein phosphatase 1 regulatory subunit 3B (Ppp1r3b) promotes hepatic glycogen synthesis and thereby regulates fasting energy homeostasis. <i>Journal of Biological Chemistry</i> , 2017, 292, 10444-10454.	3.4	54
121	Loss of Cardioprotective Effects at the <i>ADAMTS7</i> Locus as a Result of Gene-Smoking Interactions. <i>Circulation</i> , 2017, 135, 2336-2353.	1.6	51
122	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events. <i>Circulation</i> , 2017, 135, 2494-2504.	1.6	180
123	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1933-1942.	27.0	593
124	Lack of MTTP Activity in Pluripotent Stem Cell-Derived Hepatocytes and Cardiomyocytes Abolishes apoB Secretion and Increases Cell Stress. <i>Cell Reports</i> , 2017, 19, 1456-1466.	6.4	36
125	Text mining applied to electronic cardiovascular procedure reports to identify patients with trileaflet aortic stenosis and coronary artery disease. <i>Journal of Biomedical Informatics</i> , 2017, 72, 77-84.	4.3	26
126	Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms. <i>Nature Genetics</i> , 2017, 49, 1113-1119.	21.4	260



#	ARTICLE	IF	CITATIONS
127	Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 211-221.	27.0	633
128	Genetic-Variation-Driven Gene-Expression Changes Highlight Genes with Important Functions for Kidney Disease. <i>American Journal of Human Genetics</i> , 2017, 100, 940-953.	6.2	81
129	ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2054-2063.	2.8	348
130	A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a Potential Treatment for Hypercholesterolemia. <i>Cell Stem Cell</i> , 2017, 20, 478-489.e5.	11.1	92
131	Large, Diverse Population Cohorts of hiPSCs and Derived Hepatocyte-like Cells Reveal Functional Genetic Variation at Blood Lipid-Associated Loci. <i>Cell Stem Cell</i> , 2017, 20, 558-570.e10.	11.1	138
132	Exome-wide association study of plasma lipids in >300,000 individuals. <i>Nature Genetics</i> , 2017, 49, 1758-1766.	21.4	470
133	Fine Mapping and Functional Analysis Reveal a Role of SLC22A1 in Acylcarnitine Transport. <i>American Journal of Human Genetics</i> , 2017, 101, 489-502.	6.2	52
134	A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. <i>Nature Medicine</i> , 2017, 23, 1086-1094.	30.7	88
135	New insights into the role of glycosylation in lipoprotein metabolism. <i>Current Opinion in Lipidology</i> , 2017, 28, 502-506.	2.7	17
136	Can changes in the plasma lipidome help explain the cardiovascular benefits of the Mediterranean diet?. <i>American Journal of Clinical Nutrition</i> , 2017, 106, 965-966.	4.7	1
137	Polygenic determinants in extremes of high-density lipoprotein cholesterol. <i>Journal of Lipid Research</i> , 2017, 58, 2162-2170.	4.2	49
138	Large-Scale Analysis of Determinants, Stability, and Heritability of High-Density Lipoprotein Cholesterol Efflux Capacity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1956-1962.	2.4	33
139	Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 381.	7.4	138
140	Oral Apolipoprotein A-II Mimetic 4F Lowers HDL Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial. <i>Clinical and Translational Science</i> , 2017, 10, 455-469.	3.1	56
141	HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics. <i>Current Cardiology Reports</i> , 2017, 19, 132.	2.9	85
142	Paradoxical coronary artery disease in humans with hyperalphalipoproteinemia is associated with distinct differences in the high-density lipoprotein phosphosphingolipidome. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1192-1200.e3.	1.5	9
143	Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. <i>Nature Genetics</i> , 2017, 49, 1450-1457.	21.4	218
144	Hepatic metal ion transporter ZIP8 regulates manganese homeostasis and manganese-dependent enzyme activity. <i>Journal of Clinical Investigation</i> , 2017, 127, 2407-2417.	8.2	121

#	ARTICLE	IF	CITATIONS
145	mTORC1 stimulates phosphatidylcholine synthesis to promote triglyceride secretion. <i>Journal of Clinical Investigation</i> , 2017, 127, 4207-4215.	8.2	71
146	TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis. <i>Nature</i> , 2016, 535, 303-307.	27.8	72
147	Phenomenal value for human health. <i>Science</i> , 2016, 354, 1534-1536.	12.6	12
148	Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2578-2589.	2.8	723
149	Targeted exonic sequencing of GWAS loci in the high extremes of the plasma lipids distribution. <i>Atherosclerosis</i> , 2016, 250, 63-68.	0.8	11
150	Coding Variation in <i>ANGPTL4</i> , <i>LPL</i> and <i>SVEP1</i> and the Risk of Coronary Disease. <i>New England Journal of Medicine</i> , 2016, 374, 1134-1144.	27.0	427
151	Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1137-1144.e3.	1.5	26
152	Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1295-1302.	0.6	12
153	Loss of Function of <i>GALNT2</i> Lowers High-Density Lipoproteins in Humans, Nonhuman Primates, and Rodents. <i>Cell Metabolism</i> , 2016, 24, 234-245.	16.2	103
154	Targeting ApoC-III to Reduce Coronary Disease Risk. <i>Current Atherosclerosis Reports</i> , 2016, 18, 54.	4.8	31
155	Improving cardiovascular outcomes by intensifying low density lipoprotein lowering therapy in high-risk patients. <i>European Heart Journal</i> , 2016, 37, 3585-3587.	2.2	3
156	Therapeutic Targets of Triglyceride Metabolism as Informed by Human Genetics. <i>Trends in Molecular Medicine</i> , 2016, 22, 328-340.	6.7	27
157	Recent advances in the pharmacological management of hypercholesterolaemia. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 436-446.	11.4	28
158	Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. <i>Science</i> , 2016, 351, 1166-1171.	12.6	438
159	Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 240-249.	5.1	170
160	From Loci to Biology. <i>Circulation Research</i> , 2016, 118, 586-606.	4.5	54
161	New Therapeutic Approaches to the Treatment of Dyslipidemia. <i>Cell Metabolism</i> , 2016, 23, 405-412.	16.2	67
162	Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 994-1002.	2.4	32

#	ARTICLE	IF	CITATIONS
163	Sortilin mediates vascular calcification via its recruitment into extracellular vesicles. <i>Journal of Clinical Investigation</i> , 2016, 126, 1323-1336.	8.2	196
164	Tribbles-1: a novel regulator of hepatic lipid metabolism in humans. <i>Biochemical Society Transactions</i> , 2015, 43, 1079-1084.	3.4	20
165	HDL-cholesterol and cardiovascular disease. <i>Current Opinion in Cardiology</i> , 2015, 30, 536-542.	1.8	59
166	High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1515-1519.	2.4	83
167	Triglyceride-Rich Lipoproteins and Coronary Artery Disease Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, e3-9.	2.4	61
168	Lipoprotein Physiology. <i>Contemporary Endocrinology</i> , 2015, , 1-12.	0.1	2
169	Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet, The</i> , 2015, 386, 452-460.	13.7	173
170	Accelerating the Pace of Atherosclerosis Research. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 11-12.	2.4	27
171	Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. <i>Lancet Diabetes and Endocrinology,the</i> , 2015, 3, 507-513.	11.4	389
172	The Agenda for Familial Hypercholesterolemia. <i>Circulation</i> , 2015, 132, 2167-2192.	1.6	539
173	Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2201-2210.	2.8	105
174	Macrophage Sortilin Promotes LDL Uptake, Foam Cell Formation, and Atherosclerosis. <i>Circulation Research</i> , 2015, 116, 789-796.	4.5	149
175	Plasma Apolipoprotein C-III Levels, Triglycerides, and Coronary Artery Calcification in Type 2 Diabetics. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1880-1888.	2.4	60
176	Potent peroxisome proliferator-activated receptor- $\alpha$ agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. <i>European Heart Journal</i> , 2015, 36, 3020-3022.	2.2	29
177	Human Genetics of Atherothrombotic Disease and its Risk Factors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 741-747.	2.4	9
178	A comprehensive 1000 Genomes- $\alpha$ -based genome-wide association meta-analysis of coronary artery disease. <i>Nature Genetics</i> , 2015, 47, 1121-1130.	21.4	2,054
179	A systematic study of modulation of ADAM-mediated ectodomain shedding by site-specific O-glycosylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14623-14628.	7.1	98
180	Effects of Niacin, Statin, and Fenofibrate on Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Patients With Dyslipidemia. <i>American Journal of Cardiology</i> , 2015, 115, 178-182.	1.6	51

#	ARTICLE	IF	CITATIONS
181	Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. <i>Nature</i> , 2015, 518, 102-106.	27.8	581
182	Tribbles-1 regulates hepatic lipogenesis through posttranscriptional regulation of C/EBP $\beta$ . <i>Journal of Clinical Investigation</i> , 2015, 125, 3809-3818.	8.2	84
183	Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. <i>Journal of Clinical Investigation</i> , 2015, 125, 3819-3830.	8.2	72
184	Generation of iPSCs as a Pooled Culture Using Magnetic Activated Cell Sorting of Newly Reprogrammed Cells. <i>PLoS ONE</i> , 2015, 10, e0134995.	2.5	30
185	Spotlight on HDL biology: new insights in metabolism, function, and translation. <i>Cardiovascular Research</i> , 2014, 103, 337-340.	3.8	16
186	AAV Vectors Expressing LDLR Gain-of-Function Variants Demonstrate Increased Efficacy in Mouse Models of Familial Hypercholesterolemia. <i>Circulation Research</i> , 2014, 115, 591-599.	4.5	44
187	Lomitapide and Mipomersen. <i>Circulation</i> , 2014, 129, 1022-1032.	1.6	223
188	Inhibition of Endothelial Lipase Activity by Sphingomyelin in the Lipoproteins. <i>Lipids</i> , 2014, 49, 987-996.	1.7	13
189	Sortilin and lipoprotein metabolism. <i>Current Opinion in Lipidology</i> , 2014, 25, 350-357.	2.7	76
190	Differential Association of Plasma Angiopoietin-Like Proteins 3 and 4 With Lipid and Metabolic Traits. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1057-1063.	2.4	66
191	Association of Low-Frequency and Rare Coding-Sequence Variants with Blood Lipids and Coronary Heart Disease in 56,000 Whites and Blacks. <i>American Journal of Human Genetics</i> , 2014, 94, 223-232.	6.2	287
192	Future of Cholesteryl Ester Transfer Protein Inhibitors. <i>Annual Review of Medicine</i> , 2014, 65, 385-403.	12.2	62
193	Shared Genetic Susceptibility to Ischemic Stroke and Coronary Artery Disease. <i>Stroke</i> , 2014, 45, 24-36.	2.0	302
194	Inactivating Mutations in <i>NPC1L1</i> and Protection from Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2014, 371, 2072-2082.	27.0	386
195	Higher plasma CXCL12 levels predict incident myocardial infarction and death in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort study. <i>European Heart Journal</i> , 2014, 35, 2115-2122.	2.2	41
196	Genetics of lipid traits: Genome-wide approaches yield new biology and clues to causality in coronary artery disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 2010-2020.	3.8	9
197	Cardiovascular prevention—end of the road for niacin?. <i>Nature Reviews Endocrinology</i> , 2014, 10, 646-647.	9.6	9
198	HDL and cardiovascular disease. <i>Lancet</i> , The, 2014, 384, 618-625.	13.7	540

#	ARTICLE	IF	CITATIONS
199	Lipoproteins as Biomarkers and Therapeutic Targets in the Setting of Acute Coronary Syndrome. <i>Circulation Research</i> , 2014, 114, 1880-1889.	4.5	38
200	Apolipoprotein A-I and Cholesterol Efflux. <i>Circulation Research</i> , 2014, 114, 1681-1683.	4.5	17
201	Lipidomic Analyses of Female Mice Lacking Hepatic Lipase and Endothelial Lipase Indicate Selective Modulation of Plasma Lipid Species. <i>Lipids</i> , 2014, 49, 505-515.	1.7	9
202	Decreased Cholesterol Efflux Capacity and Atherogenic Lipid Profile in Young Women With PCOS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E841-E847.	3.6	54
203	Opposing Effects of ABCG5/8 Function on Myocardial Infarction and Gallstone Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2129-2130.	2.8	7
204	A novel ApoA-I truncation (ApoA-I Mytilene) associated with decreased ApoA-I production. <i>Atherosclerosis</i> , 2014, 235, 470-476.	0.8	11
205	Genetics of Lipid Traits and Relationship to Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2013, 15, 396.	2.9	13
206	High-density lipoproteins: A consensus statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2013, 7, 484-525.	1.5	276
207	Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. <i>European Journal of Heart Failure</i> , 2013, 15, 1215-1219.	7.1	49
208	Discovery and refinement of loci associated with lipid levels. <i>Nature Genetics</i> , 2013, 45, 1274-1283.	21.4	2,641
209	Common variants associated with plasma triglycerides and risk for coronary artery disease. <i>Nature Genetics</i> , 2013, 45, 1345-1352.	21.4	754
210	Secretory Phospholipase A2-IIA and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1966-1976.	2.8	115
211	Large-scale association analysis identifies new risk loci for coronary artery disease. <i>Nature Genetics</i> , 2013, 45, 25-33.	21.4	1,439
212	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. <i>Lancet</i> , The, 2013, 381, 40-46.	13.7	624
213	The Addition of Niacin to Statin Therapy Improves High-Density Lipoprotein Cholesterol Levels But Not Metrics of Functionality. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1909-1910.	2.8	71
214	Apolipoprotein E-mediated cell cycle arrest linked to p27 and the Cox2-dependent repression of miR221/222. <i>Atherosclerosis</i> , 2013, 227, 65-71.	0.8	25
215	Lymphatics as a New Active Player in Reverse Cholesterol Transport. <i>Cell Metabolism</i> , 2013, 17, 627-628.	16.2	6
216	Cholesterol Efflux Capacity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1449-1451.	2.4	30

#	ARTICLE	IF	CITATIONS
217	Beyond LDL Cholesterol in Assessing Cardiovascular Risk: apo B or LDL-P?. <i>Clinical Chemistry</i> , 2013, 59, 723-725.	3.2	17
218	Endothelial Lipase Is a Critical Determinant of High-Density Lipoprotein-Dependent Signaling in Vascular Endothelium. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1788-1794.	2.4	36
219	Nuclear Receptors and microRNA-144 Coordinately Regulate Cholesterol Efflux. <i>Circulation Research</i> , 2013, 112, 1529-1531.	4.5	8
220	Mighty Minipig in Fight Against Cardiovascular Disease. <i>Science Translational Medicine</i> , 2013, 5, 166fs1.	12.4	16
221	Expression of Type IIA Secretory Phospholipase A <sub>2</sub> Inhibits Cholesteryl Ester Transfer Protein Activity in Transgenic Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2707-2714.	2.4	8
222	Biodistribution of AAV8 Vectors Expressing Human Low-Density Lipoprotein Receptor in a Mouse Model of Homozygous Familial Hypercholesterolemia. <i>Human Gene Therapy Clinical Development</i> , 2013, 24, 154-160.	3.1	34
223	Adeno-Associated Virus Serotype 8 Gene Therapy Leads to Significant Lowering of Plasma Cholesterol Levels in Humanized Mouse Models of Homozygous and Heterozygous Familial Hypercholesterolemia. <i>Human Gene Therapy</i> , 2013, 24, 19-26.	2.7	65
224	Exome Sequencing and Directed Clinical Phenotyping Diagnose Cholesterol Ester Storage Disease Presenting as Autosomal Recessive Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2909-2914.	2.4	87
225	Angptl3 Deficiency Is Associated With Increased Insulin Sensitivity, Lipoprotein Lipase Activity, and Decreased Serum Free Fatty Acids. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1706-1713.	2.4	141
226	Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics. <i>Clinical Lipidology</i> , 2013, 8, 635-648.	0.4	11
227	Lipoprotein Disorders. , 2013, , 501-515.		0
228	Effect of interleukin 1 $\beta$ inhibition in cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2012, 23, 548-553.	2.7	68
229	Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression. <i>Science Translational Medicine</i> , 2012, 4, 148ra115.	12.4	102
230	Approach to the Patient with Extremely Low HDL-Cholesterol. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3399-3407.	3.6	69
231	Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. <i>Lancet</i> , The, 2012, 379, 1205-1213.	13.7	668
232	Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. <i>Lancet</i> , The, 2012, 380, 572-580.	13.7	1,937
233	ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma. <i>Journal of Lipid Research</i> , 2012, 53, 929-940.	4.2	25
234	Cardiovascular Protection by ApoE and ApoE-HDL Linked to Suppression of ECM Gene Expression and Arterial Stiffening. <i>Cell Reports</i> , 2012, 2, 1259-1271.	6.4	159

#	ARTICLE	IF	CITATIONS
235	Prediabetic Obese Adolescents have a More Atherogenic Lipoprotein Profile Compared with Normoglycemic Obese Peers. <i>Journal of Pediatrics</i> , 2012, 161, 881-886.	1.8	16
236	Is it time to revise the HDL cholesterol hypothesis?. <i>Nature Medicine</i> , 2012, 18, 1344-1346.	30.7	241
237	Secreted miRNAs suppress atherogenesis. <i>Nature Cell Biology</i> , 2012, 14, 233-235.	10.3	17
238	Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci. <i>American Journal of Human Genetics</i> , 2012, 91, 823-838.	6.2	227
239	Targeting High Density Lipoproteins in the Prevention of Cardiovascular Disease?. <i>Current Cardiology Reports</i> , 2012, 14, 684-691.	2.9	29
240	Cholesterol Efflux and Atheroprotection. <i>Circulation</i> , 2012, 125, 1905-1919.	1.6	772
241	Genomic medicine in the prevention and treatment of atherosclerotic cardiovascular disease. <i>Personalized Medicine</i> , 2012, 9, 395-404.	1.5	3
242	Sortilin as a Regulator of Lipoprotein Metabolism. <i>Current Atherosclerosis Reports</i> , 2012, 14, 211-218.	4.8	45
243	IL-1 and atherosclerosis: a murine twist to an evolving human story. <i>Journal of Clinical Investigation</i> , 2012, 122, 27-30.	8.2	36
244	Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 1677-1687.	8.2	96
245	Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. <i>Journal of Clinical Investigation</i> , 2012, 122, 2807-2816.	8.2	190
246	Multi-Ethnic Analysis of Lipid-Associated Loci: The NHLBI CARE Project. <i>PLoS ONE</i> , 2012, 7, e36473.	2.5	46
247	Biliary Sterol Secretion Is Required for Functional In Vivo Reverse Cholesterol Transport in Mice. <i>Gastroenterology</i> , 2011, 140, 1043-1051.	1.3	63
248	The Anti-Oxidative Capacity of High-Density Lipoprotein Is Reduced in Acute Coronary Syndrome But Not in Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2068-2075.	2.8	105
249	Novel HDL-directed pharmacotherapeutic strategies. <i>Nature Reviews Cardiology</i> , 2011, 8, 266-277.	13.7	136
250	Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. <i>Lancet, The</i> , 2011, 377, 383-392.	13.7	466
251	Functional validation of new pathways in lipoprotein metabolism identified by human genetics. <i>Current Opinion in Lipidology</i> , 2011, 22, 123-128.	2.7	34
252	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. <i>Nature Genetics</i> , 2011, 43, 333-338.	21.4	1,685

#	ARTICLE	IF	CITATIONS
253	PPAR $\beta$ activation redirects macrophage cholesterol from fecal excretion to adipose tissue uptake in mice via SR-BI. <i>Biochemical Pharmacology</i> , 2011, 81, 934-941.	4.4	19
254	Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis. <i>New England Journal of Medicine</i> , 2011, 364, 127-135.	27.0	1,686
255	Adiponectin Is Associated with Favorable Lipoprotein Profile, Independent of BMI and Insulin Resistance, in Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1549-1554.	3.6	41
256	Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. <i>Journal of Lipid Research</i> , 2011, 52, 361-373.	4.2	129
257	Pharmacologic Suppression of Hepatic ATP-Binding Cassette Transporter 1 Activity in Mice Reduces High-Density Lipoprotein Cholesterol Levels but Promotes Reverse Cholesterol Transport. <i>Circulation</i> , 2011, 124, 1382-1390.	1.6	61
258	Dense Genotyping of Candidate Gene Loci Identifies Variants Associated With High-Density Lipoprotein Cholesterol. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 145-155.	5.1	71
259	Adipose Modulation of High-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2011, 124, 1602-1605.	1.6	37
260	Mining the LIPG Allelic Spectrum Reveals the Contribution of Rare and Common Regulatory Variants to HDL Cholesterol. <i>PLoS Genetics</i> , 2011, 7, e1002393.	3.5	32
261	Peroxisome Proliferator-Activated Receptor- $\alpha$ Activation Promotes Macrophage Reverse Cholesterol Transport Through a Liver X Receptor-Dependent Pathway. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1276-1282.	2.4	47
262	Genome-Wide Association Study of Coronary Heart Disease and Its Risk Factors in 8,090 African Americans: The NHLBI CARE Project. <i>PLoS Genetics</i> , 2011, 7, e1001300.	3.5	290
263	Influence of Apolipoprotein A-I Domain Structure on Macrophage Reverse Cholesterol Transport in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 320-327.	2.4	25
264	Atherogenic Lipid Metabolism in Obesity. , 2011, , 293-309.		1
265	Update on the Role of Endothelial Lipase in High-Density Lipoprotein Metabolism, Reverse Cholesterol Transport, and Atherosclerosis. <i>Circulation Journal</i> , 2010, 74, 2263-2270.	1.6	100
266	Clinical Implications of Lipid Genetics for Cardiovascular Disease. <i>Current Cardiovascular Risk Reports</i> , 2010, 4, 461-468.	2.0	22
267	Future Therapeutic Directions in Reverse Cholesterol Transport. <i>Current Atherosclerosis Reports</i> , 2010, 12, 73-81.	4.8	93
268	CXCL12: A New Player in Coronary Disease Identified through Human Genetics. <i>Trends in Cardiovascular Medicine</i> , 2010, 20, 204-209.	4.9	46
269	Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes. <i>Biochemical Pharmacology</i> , 2010, 80, 1450-1457.	4.4	46
270	Short-Term Treatment with High-Dose Atorvastatin Reduces LDL Cholesterol but Shows no Anti-Inflammatory Effects in Normolipidemic Subjects with Normal CRP Levels. <i>Clinical and Translational Science</i> , 2010, 3, 140-146.	3.1	14



#	ARTICLE	IF	CITATIONS
271	From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. <i>Nature</i> , 2010, 466, 714-719.	27.8	1,018
272	Biological, clinical and population relevance of 95 loci for blood lipids. <i>Nature</i> , 2010, 466, 707-713.	27.8	3,249
273	Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. <i>Nature Genetics</i> , 2010, 42, 692-697.	21.4	181
274	Gene Therapy in a Humanized Mouse Model of Familial Hypercholesterolemia Leads to Marked Regression of Atherosclerosis. <i>PLoS ONE</i> , 2010, 5, e13424.	2.5	69
275	Tissue-Specific Liver X Receptor Activation Promotes Macrophage Reverse Cholesterol Transport In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 781-786.	2.4	107
276	Could Exercise Metabolomics Pave the Way for Gymnomimetics?. <i>Science Translational Medicine</i> , 2010, 2, 41ps35.	12.4	11
277	Genetic Variants Influencing Circulating Lipid Levels and Risk of Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 2264-2276.	2.4	369
278	Polyphenols and Cholesterol Efflux. <i>Circulation Research</i> , 2010, 106, 627-629.	4.5	18
279	Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. <i>Journal of Clinical Investigation</i> , 2010, 120, 2889-2899.	8.2	71
280	Impact of Combined Deficiency of Hepatic Lipase and Endothelial Lipase on the Metabolism of Both High-Density Lipoproteins and Apolipoprotein B-Containing Lipoproteins. <i>Circulation Research</i> , 2010, 107, 357-364.	4.5	70
281	The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol From Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 796-801.	2.4	348
282	Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies. <i>Clinical Lipidology</i> , 2010, 5, 793-809.	0.4	13
283	Lipoprotein Disorders. , 2010, , 269-288.		1
284	Trib1 is a lipid- and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 4410-4414.	8.2	127
285	Identification of the Active Form of Endothelial Lipase, a Homodimer in a Head-to-Tail Conformation. <i>Journal of Biological Chemistry</i> , 2009, 284, 23322-23330.	3.4	40
286	Lecithin: Cholesterol Acyltransferase Expression Has Minimal Effects on Macrophage Reverse Cholesterol Transport In Vivo. <i>Circulation</i> , 2009, 120, 160-169.	1.6	87
287	The T1111 variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations. <i>European Heart Journal</i> , 2009, 30, 1584-1589.	2.2	39
288	Fish Oil Promotes Macrophage Reverse Cholesterol Transport in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1502-1508.	2.4	50

#	ARTICLE	IF	CITATIONS
289	Macrophage Reverse Cholesterol Transport in Mice Expressing ApoA-I Milano. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1496-1501.	2.4	53
290	Lecithin: Cholesterol Acyltransferase and Atherosclerosis. <i>Circulation</i> , 2009, 120, 549-552.	1.6	20
291	Potent and Selective PPAR- $\alpha$ Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 140-146.	2.4	41
292	Discovery and Validation of New Molecular Targets in Treating Dyslipidemia: The Role of Human Genetics. <i>Trends in Cardiovascular Medicine</i> , 2009, 19, 195-201.	4.9	19
293	Both the Peroxisome Proliferator-Activated Receptor $\alpha$ Agonist, GW0742, and Ezetimibe Promote Reverse Cholesterol Transport in Mice by Reducing Intestinal Reabsorption of HDL-Derived Cholesterol. <i>Clinical and Translational Science</i> , 2009, 2, 127-133.	3.1	64
294	Inflammation induces fibrinogen nitration in experimental human endotoxemia. <i>Free Radical Biology and Medicine</i> , 2009, 47, 1140-1146.	2.9	30
295	Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. <i>Nature Genetics</i> , 2009, 41, 342-347.	21.4	709
296	Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. <i>Nature Genetics</i> , 2009, 41, 334-341.	21.4	990
297	Update on strategies to increase HDL quantity and function. <i>Nature Reviews Cardiology</i> , 2009, 6, 455-463.	13.7	172
298	The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. <i>Journal of Lipid Research</i> , 2009, 50, S189-S194.	4.2	488
299	Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. <i>Journal of Clinical Investigation</i> , 2009, 119, 1042-50.	8.2	162
300	Novel ENU-Induced Point Mutation in Scavenger Receptor Class B, Member 1, Results in Liver Specific Loss of SCARB1 Protein. <i>PLoS ONE</i> , 2009, 4, e6521.	2.5	15
301	Therapeutic Targeting of High-Density Lipoprotein Metabolism. , 2009, , 544-552.		0
302	Lipoprotein Disorders. , 2009, , 634-651.		0
303	Longitudinal Evaluation and Assessment of Cardiovascular Disease in Patients With Homozygous Familial Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2008, 102, 1438-1443.	1.6	146
304	The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1653-1662.	2.8	104
305	Laboratory Assessment of HDL Heterogeneity and Function. <i>Clinical Chemistry</i> , 2008, 54, 788-800.	3.2	164
306	Beyond High-Density Lipoprotein Cholesterol Levels. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2199-2211.	2.8	231

#	ARTICLE	IF	CITATIONS
307	Knockdown of Acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2008, 1781, 97-104.	2.4	79
308	Translating molecular discoveries into new therapies for atherosclerosis. <i>Nature</i> , 2008, 451, 904-913.	27.8	436
309	Structure-function properties of the apoE-dependent COX-2 pathway in vascular smooth muscle cells. <i>Atherosclerosis</i> , 2008, 196, 201-209.	0.8	15
310	Cholesteryl Ester Transfer Protein (CETP) Inhibitors: Is There Life After Torcetrapib?. <i>Cardiology Clinics</i> , 2008, 26, 537-546.	2.2	18
311	Dyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1007-1022.	1.5	14
312	Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. <i>Journal of Lipid Research</i> , 2008, 49, 1344-1352.	4.2	266
313	When HDL Gets Fat   . <i>Circulation Research</i> , 2008, 103, 131-132.	4.5	7
314	Upregulation of Macrophage Endothelial Lipase by Toll-Like Receptors 4 and 3 Modulates Macrophage Interleukin-10 and -12 Production. <i>Circulation Research</i> , 2007, 100, 1008-1015.	4.5	24
315	Expression of Cholesteryl Ester Transfer Protein in Mice Promotes Macrophage Reverse Cholesterol Transport. <i>Circulation</i> , 2007, 116, 1267-1273.	1.6	135
316	Wild-Type ApoA-I and the Milano Variant Have Similar Abilities to Stimulate Cellular Lipid Mobilization and Efflux. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2022-2029.	2.4	46
317	Glycosylation of endothelial lipase at asparagine-116 reduces activity and the hydrolysis of native lipoproteins in vitro and in vivo. <i>Journal of Lipid Research</i> , 2007, 48, 1132-1139.	4.2	14
318	N-Glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-I-containing high density lipoproteins. <i>Journal of Lipid Research</i> , 2007, 48, 2047-2057.	4.2	23
319	Molecular regulation of macrophage reverse cholesterol transport. <i>Current Opinion in Cardiology</i> , 2007, 22, 368-372.	1.8	104
320	Lipases as Modulators of Atherosclerosis in Murine Models. <i>Current Drug Targets</i> , 2007, 8, 1307-1319.	2.1	35
321	Mechanisms of Disease: HDL metabolism as a target for novel therapies. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 102-109.	3.3	59
322	Effect of Insulin Resistance, Dyslipidemia, and Intra-abdominal Adiposity on the Development of Cardiovascular Disease and Diabetes Mellitus. <i>American Journal of Medicine</i> , 2007, 120, S12-S18.	1.5	254
323	Hepatic Proprotein Convertases Modulate HDL Metabolism. <i>Cell Metabolism</i> , 2007, 6, 129-136.	16.2	117
324	Illuminating HDL " Is It Still a Viable Therapeutic Target?. <i>New England Journal of Medicine</i> , 2007, 357, 2180-2183.	27.0	121

#	ARTICLE	IF	CITATIONS
325	A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction. <i>Science</i> , 2007, 316, 1491-1493.	12.6	1,485
326	Flaxseed Reduces Plasma Cholesterol Levels in Hypercholesterolemic Mouse Models. <i>Journal of the American College of Nutrition</i> , 2007, 26, 66-75.	1.8	56
327	Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2007, 356, 148-156.	27.0	504
328	Obesity and Atherogenic Dyslipidemia. <i>Gastroenterology</i> , 2007, 132, 2181-2190.	1.3	129
329	CXCL16 Is a Marker of Inflammation, Atherosclerosis, and Acute Coronary Syndromes in Humans. <i>Journal of the American College of Cardiology</i> , 2007, 49, 442-449.	2.8	148
330	Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. <i>Cardiovascular Diabetology</i> , 2007, 6, 15.	6.8	64
331	'Multipurpose oxidase' in atherogenesis. <i>Nature Medicine</i> , 2007, 13, 1146-1147.	30.7	16
332	Liver X Receptor and Farnesoid X Receptor as Therapeutic Targets. <i>American Journal of Cardiology</i> , 2007, 100, S15-S19.	1.6	45
333	Endocannabinoid Antagonism: Blocking the Excess in the Treatment of High-Risk Abdominal Obesity. <i>Trends in Cardiovascular Medicine</i> , 2007, 17, 35-43.	4.9	20
334	Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. <i>Journal of Clinical Investigation</i> , 2007, 117, 2216-2224.	8.2	498
335	Genetic Disorders of Lipoprotein Metabolism. , 2007, , 23-35.		1
336	Anti-Inflammatory and Antioxidant Functions of High Density Lipoproteins. , 2006, , 399-436.		0
337	Effects of Rosiglitazone on Lipids, Adipokines, and Inflammatory Markers in Nondiabetic Patients With Low High-Density Lipoprotein Cholesterol and Metabolic Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 624-630.	2.4	137
338	Persistent liver expression of murine apoA-I using vectors based on adeno-associated viral vectors serotypes 5 and 1. <i>Atherosclerosis</i> , 2006, 186, 65-73.	0.8	27
339	Molecular regulation of HDL metabolism and function: implications for novel therapies. <i>Journal of Clinical Investigation</i> , 2006, 116, 3090-3100.	8.2	480
340	Apolipoprotein E and Coronary Disease: A Puzzling Paradox. <i>PLoS Medicine</i> , 2006, 3, e258.	8.4	21
341	A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. <i>Nature Genetics</i> , 2006, 38, 68-74.	21.4	339
342	Human genetics of variation in high-density lipoprotein cholesterol. <i>Current Atherosclerosis Reports</i> , 2006, 8, 198-205.	4.8	39

#	ARTICLE	IF	CITATIONS
343	Macrophage Reverse Cholesterol Transport. <i>Circulation</i> , 2006, 113, 2548-2555.	1.6	485
344	Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 182-188.	2.4	160
345	High-Density Lipoprotein Hydrolysis by Endothelial Lipase Activates PPAR $\alpha$ . <i>Circulation Research</i> , 2006, 98, 490-498.	4.5	84
346	Endothelial lipase is less effective at influencing HDL metabolism in vivo in mice expressing apoA-II. <i>Journal of Lipid Research</i> , 2006, 47, 2191-2197.	4.2	18
347	Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport. <i>Circulation</i> , 2006, 113, 1140-1150.	1.6	93
348	Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB production. <i>Journal of Lipid Research</i> , 2006, 47, 2297-2305.	4.2	78
349	Complete Prevention of Atherosclerosis in ApoE-Deficient Mice by Hepatic Human ApoE Gene Transfer With Adeno-Associated Virus Serotypes 7 and 8. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1852-1857.	2.4	52
350	Pharmacological Activation of Liver X Receptors Promotes Reverse Cholesterol Transport In Vivo. <i>Circulation</i> , 2006, 113, 90-97.	1.6	344
351	Effects of the Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib on Apolipoprotein B100 Metabolism in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1350-1356.	2.4	68
352	Substrate specificity of lipoprotein lipase and endothelial lipase: studies of lid chimeras. <i>Journal of Lipid Research</i> , 2006, 47, 1803-1811.	4.2	44
353	Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport. <i>Current Opinion in Cardiology</i> , 2005, 20, 301-306.	1.8	28
354	Endothelial Lipase: A Novel Drug Target for HDL and Atherosclerosis?. , 2005, , 139-153.		1
355	Current drug options for raising HDL cholesterol. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 15-23.	0.9	6
356	Endothelial Lipase Concentrations Are Increased in Metabolic Syndrome and Associated with Coronary Atherosclerosis. <i>PLoS Medicine</i> , 2005, 3, e22.	8.4	147
357	Proprotein Convertases Are Responsible for Proteolysis and Inactivation of Endothelial Lipase. <i>Journal of Biological Chemistry</i> , 2005, 280, 36551-36559.	3.4	91
358	Complete Deficiency of the Low-Density Lipoprotein Receptor Is Associated With Increased Apolipoprotein B-100 Production. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 560-565.	2.4	74
359	Gene therapy for lipoprotein disorders. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 1029-1038.	3.1	7
360	Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1057-1064.	2.4	228

#	ARTICLE	IF	CITATIONS
361	ATVB In Focus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 480-481.	2.4	5
362	Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. Journal of Lipid Research, 2005, 46, 2023-2028.	4.2	220
363	Increased Atherosclerosis in Mice Lacking Apolipoprotein A-I Attributable to Both Impaired Reverse Cholesterol Transport and Increased Inflammation. Circulation Research, 2005, 97, 763-771.	4.5	165
364	Regulated expression of endothelial lipase by porcine brain capillary endothelial cells constituting the blood-brain barrier. Journal of Neurochemistry, 2005, 94, 109-119.	3.9	37
365	New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport. Circulation Research, 2005, 96, 1221-1232.	4.5	901
366	Lipoproteins, macrophage function, and atherosclerosis: Beyond the foam cell?. Cell Metabolism, 2005, 1, 223-230.	16.2	125
367	Endothelial lipase provides an alternative pathway for FFA uptake in lipoprotein lipase-deficient mouse adipose tissue. Journal of Clinical Investigation, 2005, 115, 161-167.	8.2	23
368	Endothelial lipase provides an alternative pathway for FFA uptake in lipoprotein lipase-deficient mouse adipose tissue. Journal of Clinical Investigation, 2005, 115, 161-167.	8.2	42
369	Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. Journal of Clinical Investigation, 2005, 115, 2870-2874.	8.2	269
370	Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol. New England Journal of Medicine, 2004, 350, 1505-1515.	27.0	743
371	Role of N-linked glycosylation in the secretion and activity of endothelial lipase. Journal of Lipid Research, 2004, 45, 2080-2087.	4.2	29
372	Cholesteryl Ester Transfer Protein and Coronary Artery Disease. Circulation, 2004, 110, 1338-1340.	1.6	32
373	Endothelial Lipase Promotes the Catabolism of ApoB-Containing Lipoproteins. Circulation Research, 2004, 94, 1554-1561.	4.5	67
374	Structural basis of endothelial lipase tropism for HDL. FASEB Journal, 2004, 18, 1891-1893.	0.5	13
375	COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice. Science, 2004, 306, 1954-1957.	12.6	403
376	NARC-1/PCSK9 and Its Natural Mutants. Journal of Biological Chemistry, 2004, 279, 48865-48875.	3.4	544
377	The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nature Medicine, 2004, 10, 966-973.	30.7	318
378	Endothelial Lipase: A Modulator of Lipoprotein Metabolism Upregulated by Inflammation. Trends in Cardiovascular Medicine, 2004, 14, 202-206.	4.9	44

#	ARTICLE	IF	CITATIONS
379	Inhibition of cholesteryl ester transfer protein activity: A new therapeutic approach to raising high-density lipoprotein. <i>Current Atherosclerosis Reports</i> , 2004, 6, 398-405.	4.8	30
380	The triglycerideâ€“high-density lipoprotein axis: An important target of therapy?. <i>American Heart Journal</i> , 2004, 148, 211-221.	2.7	82
381	Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2004, 350, 1495-1504.	27.0	4,527
382	Antimitogenic effects of HDL and APOE mediated by Cox-2â€“dependent IP activation. <i>Journal of Clinical Investigation</i> , 2004, 113, 609-618.	8.2	41
383	Therapy to reduce risk of coronary heart disease. <i>Clinical Cardiology</i> , 2003, 26, 2-8.	1.8	17
384	Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism. <i>American Journal of Cardiology</i> , 2003, 91, 18-23.	1.6	89
385	Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. <i>American Journal of Cardiology</i> , 2003, 91, 20-23.	1.6	67
386	Regulation of reverse cholesterol transport and clinical implications. <i>American Journal of Cardiology</i> , 2003, 92, 42-49.	1.6	168
387	A tetracycline-regulated adenoviral expression system for in vivo delivery of transgenes to lung and liver. <i>Journal of Gene Medicine</i> , 2003, 5, 567-575.	2.8	20
388	Evidence That Hepatic Lipase and Endothelial Lipase Have Different Substrate Specificities for High-Density Lipoprotein Phospholipids. <i>Biochemistry</i> , 2003, 42, 13778-13785.	2.5	43
389	Management of selected lipid abnormalities: hypertriglyceridemia, isolated low HDL-cholesterol, lipoprotein(a), and lipid abnormalities in renal diseases and following solid organ transplantation. <i>Cardiology Clinics</i> , 2003, 21, 377-392.	2.2	7
390	Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: Evidence for an antiinflammatory role for lipoprotein lipase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 2730-2735.	7.1	229
391	Prostacylin Receptor Activation Inhibits Proliferation of Aortic Smooth Muscle Cells by Regulating cAMP Response Element-Binding Protein- and Pocket Protein-Dependent Cyclin A Gene Expression. <i>Molecular Pharmacology</i> , 2003, 64, 249-258.	2.3	50
392	Effects of Nonlipolytic Ligand Function of Endothelial Lipase on High Density Lipoprotein Metabolism in Vivo. <i>Journal of Biological Chemistry</i> , 2003, 278, 40688-40693.	3.4	53
393	Genetics of Increased HDL Cholesterol Levels. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1710-1712.	2.4	26
394	The Metabolic Syndrome. <i>Circulation</i> , 2003, 108, 1546-1551.	1.6	422
395	High-Density Lipoproteins as an Emerging Therapeutic Target for Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 2322.	7.4	50
396	Guggulipid for the Treatment of Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 765.	7.4	205

#	ARTICLE	IF	CITATIONS
397	Cholesteryl Ester Transfer Protein. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 160-167.	2.4	780
398	Endothelial Cells Secrete Triglyceride Lipase and Phospholipase Activities in Response to Cytokines as a Result of Endothelial Lipase. <i>Circulation Research</i> , 2003, 92, 644-650.	4.5	115
399	Apolipoprotein A-I Deficiency Results in Markedly Increased Atherosclerosis in Mice Lacking the LDL Receptor. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1914-1920.	2.4	90
400	Dose-Dependent Acceleration of High-Density Lipoprotein Catabolism by Endothelial Lipase. <i>Circulation</i> , 2003, 108, 2121-2126.	1.6	130
401	Endogenously Produced Endothelial Lipase Enhances Binding and Cellular Processing of Plasma Lipoproteins via Heparan Sulfate Proteoglycan-mediated Pathway. <i>Journal of Biological Chemistry</i> , 2003, 278, 34331-34338.	3.4	103
402	Overexpression of Apolipoprotein A-I Promotes Reverse Transport of Cholesterol From Macrophages to Feces In Vivo. <i>Circulation</i> , 2003, 108, 661-663.	1.6	403
403	Acute inflammation increases selective uptake of HDL cholesteryl esters into adrenals of mice overexpressing human sPLA <sub>2</sub> . <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2003, 285, E403-E411.	3.5	31
404	Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. <i>Journal of Clinical Investigation</i> , 2003, 111, 357-362.	8.2	197
405	Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. <i>Journal of Clinical Investigation</i> , 2003, 111, 1795-1803.	8.2	225
406	Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. <i>Journal of Clinical Investigation</i> , 2003, 111, 1795-1803.	8.2	421
407	Normal Production Rate of Apolipoprotein B in LDL Receptor-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 989-994.	2.4	43
408	Human Secretory Phospholipase A2 Mediates Decreased Plasma Levels of HDL Cholesterol and ApoA-I in Response to Inflammation in Human ApoA-I Transgenic Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1213-1218.	2.4	117
409	Identification of Genetic Variants in Endothelial Lipase in Persons With Elevated High-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2002, 106, 1321-1326.	1.6	130
410	Lipase H, a New Member of the Triglyceride Lipase Family Synthesized by the Intestine. <i>Genomics</i> , 2002, 80, 268-273.	2.9	40
411	Lipases and HDL metabolism. <i>Trends in Endocrinology and Metabolism</i> , 2002, 13, 174-178.	7.1	77
412	High-density lipoproteins and atherosclerosis. <i>American Journal of Cardiology</i> , 2002, 90, 62-70.	1.6	110
413	Characterization of the lipolytic activity of endothelial lipase. <i>Journal of Lipid Research</i> , 2002, 43, 921-929.	4.2	277
414	Characterization of the lipolytic activity of endothelial lipase. <i>Journal of Lipid Research</i> , 2002, 43, 921-9.	4.2	234



#	ARTICLE	IF	CITATIONS
415	A new feature on the cholesterol-lowering landscape. <i>Nature Medicine</i> , 2001, 7, 1282-1284.	30.7	31
416	Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. <i>American Journal of Cardiology</i> , 2001, 87, 476-479.	1.6	92
417	Does Exercise Increase HDL Cholesterol in Those Who Need It the Most?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1097-1098.	2.4	47
418	Absence of 12/15-Lipoxygenase Expression Decreases Lipid Peroxidation and Atherogenesis in Apolipoprotein E-Deficient Mice. <i>Circulation</i> , 2001, 103, 2277-2282.	1.6	225
419	The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. <i>Journal of Clinical Investigation</i> , 2001, 108, 1031-1040.	8.2	264
420	Endothelial lipase colon; a new member of the triglyceride lipase gene family. <i>Current Opinion in Lipidology</i> , 2000, 11, 141-147.	2.7	89
421	Genes influencing HDL metabolism: new perspectives and implications for atherosclerosis prevention. <i>Trends in Molecular Medicine</i> , 2000, 6, 170-175.	2.6	39
422	High-density lipoprotein metabolism: Molecular targets for new therapies for atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2000, 2, 363-372.	4.8	30
423	Hepatic Expression of Apolipoprotein E Inhibits Progression of Atherosclerosis without Reducing Cholesterol Levels in LDL Receptor-Deficient Mice. <i>Molecular Therapy</i> , 2000, 1, 189-194.	8.2	44
424	Gene Transfer and Hepatic Overexpression of the HDL Receptor SR-BI Reduces Atherosclerosis in the Cholesterol-Fed LDL Receptor-Deficient Mouse. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 721-727.	2.4	317
425	Inflammatory Markers of Coronary Risk. <i>New England Journal of Medicine</i> , 2000, 343, 1179-1182.	27.0	232
426	The Endothelium and Lipoproteins: Insights from Recent Cell Biology and Animal Studies. <i>Seminars in Thrombosis and Hemostasis</i> , 2000, 26, 521-528.	2.7	40
427	Overexpression of Secretory Phospholipase A2 Causes Rapid Catabolism and Altered Tissue Uptake of High Density Lipoprotein Cholesteryl Ester and Apolipoprotein A-I. <i>Journal of Biological Chemistry</i> , 2000, 275, 10077-10084.	3.4	149
428	Prolonged Correction of Hyperlipidemia in Mice with Familial Hypercholesterolemia Using an Adeno-Associated Viral Vector Expressing Very-Low-Density Lipoprotein Receptor. <i>Molecular Therapy</i> , 2000, 2, 256-261.	8.2	63
429	Rapid Regression of Atherosclerosis Induced by Liver-Directed Gene Transfer of ApoE in ApoE-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 2162-2170.	2.4	103
430	Regression of Atherosclerosis Induced by Liver-Directed Gene Transfer of Apolipoprotein A-I in Mice. <i>Circulation</i> , 1999, 100, 1816-1822.	1.6	352
431	A novel endothelial-derived lipase that modulates HDL metabolism. <i>Nature Genetics</i> , 1999, 21, 424-428.	21.4	461
432	Role of fibrates in the management of hypertriglyceridemia. <i>American Journal of Cardiology</i> , 1999, 83, 30-35.	1.6	36

#	ARTICLE	IF	CITATIONS
433	Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. <i>Journal of Lipid Research</i> , 1999, 40, 648-653.	4.2	59
434	Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. <i>Journal of Lipid Research</i> , 1999, 40, 2134-2139.	4.2	139
435	ABC1: connecting yellow tonsils, neuropathy, and very low HDL. <i>Journal of Clinical Investigation</i> , 1999, 104, 1015-1017.	8.2	69
436	Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. <i>Nature Medicine</i> , 1998, 4, 1189-1192.	30.7	496
437	Lipoprotein(a) levels and heart transplantation atherosclerosis. <i>American Heart Journal</i> , 1998, 136, 329-334.	2.7	10
438	Increased Formation of Distinct F <sub>2</sub> Isoprostanes in Hypercholesterolemia. <i>Circulation</i> , 1998, 98, 2822-2828.	1.6	266
439	Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models. <i>Current Opinion in Lipidology</i> , 1996, 7, 117-123.	2.7	54
440	Apolipoprotein A-II Production Rate Is a Major Factor Regulating the Distribution of Apolipoprotein A-I Among HDL Subclasses LpA-I and LpA-I:A-II in Normolipidemic Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 306-312.	2.4	65
441	Quantitation of Plasma Apolipoproteins in the Primary and Secondary Prevention of Coronary Artery Disease. <i>Annals of Internal Medicine</i> , 1994, 120, 1012.	3.9	187
442	Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. <i>Nature</i> , 1993, 365, 65-69.	27.8	472
443	Lipoprotein(a). <i>JAMA - Journal of the American Medical Association</i> , 1992, 267, 1109.	7.4	45
444	Clinical and Laboratory Findings in the Oculocerebrorenal Syndrome of Lowe, with Special Reference to Growth and Renal Function. <i>New England Journal of Medicine</i> , 1991, 324, 1318-1325.	27.0	127
445	ILRUN Promotes Atherosclerosis Through Lipid-Dependent and Lipid-Independent Factors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 0, , .	2.4	2